Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction

Advances in cancer therapy have resulted in more cancer therapy-related cardiac dysfunction (CTRCD), which is the main cause of death in older female survivors of breast cancer. Traditionally, guideline-recommended medications for heart failure, such as beta-blockers and angiotensin-converting enzym...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Qianlan, Chen, Zijun, Li, Tingming, Wang, Liya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802132/
https://www.ncbi.nlm.nih.gov/pubmed/34986674
http://dx.doi.org/10.1177/03000605211067909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802132/
https://www.ncbi.nlm.nih.gov/pubmed/34986674
http://dx.doi.org/10.1177/03000605211067909

Ejemplares similares